Chester County News and Community Website
WILMINGTON, DE — AstraZeneca said the SAPHNELO Pen has received approval from the U.S. Food and Drug Administration for self-administration in adults with systemic lupus erythematosus receiving standard therapy.
FDA Approves AstraZeneca Lupus Autoinjector Treatment Read More WILMINGTON, DE — AstraZeneca reported that its experimental drug tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease in a Phase III trial.
AstraZeneca Drug Reduces COPD Exacerbations in Phase III Trial Read More WILMINGTON, DE — AstraZeneca reported that its drug combination including IMFINZI and IMJUDO, used with lenvatinib and transarterial chemoembolization, improved progression-free survival in patients with unresectable liver cancer eligible for …
AstraZeneca Trial Shows Improved Outcomes in Liver Cancer Study Read More WILMINGTON, DE — AstraZeneca (NYSE: AZN) said its experimental drug tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease in two Phase III trials, according to results from …
AstraZeneca Drug Cuts COPD Exacerbations in Phase III Trials Read More
WILMINGTON, DE — AstraZeneca (Nasdaq: AZN) announced a national public health campaign encouraging Americans to speak with their doctors about cancer risk and screening, partnering with actor Joshua Jackson and …
AstraZeneca Launches Cancer Screening Campaign With Joshua Jackson Read More WILMINGTON, DE — The U.S. Food and Drug Administration has accepted and granted Priority Review to a supplemental application for ENHERTU, a breast cancer treatment developed by AstraZeneca and Daiichi …
FDA Grants Priority Review to ENHERTU for Early Breast Cancer Use Read More WILMINGTON, DE — AstraZeneca said the U.S. Food and Drug Administration has approved CALQUENCE (acalabrutinib) in combination with venetoclax as a fixed-duration, all-oral treatment for adults with chronic lymphocytic leukemia …
FDA Approves AstraZeneca’s CALQUENCE Combo for CLL, SLL Read More WILMINGTON, DE — AstraZeneca (NYSE: AZN) said full results from the Phase III KALOS and LOGOS trials, published in The Lancet Respiratory Medicine, showed its triple-combination inhaler BREZTRI Aerosphere significantly …
AstraZeneca Reports Phase III Results for BREZTRI in Asthma Read More WILMINGTON, DE — AstraZeneca announced it has awarded $3.4 million to nonprofit organizations across the United States through its Accelerate Change Together on Health Equity initiative to support programs addressing …
AstraZeneca Awards $3.4 Million to U.S. Health Equity Programs Read More WILMINGTON, DE — AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review by the U.S. Food and Drug Administration for …
DATROWAY Gains Priority Review for Aggressive Breast Cancer Read More